Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Iovance Receives FDA Allowance For IOV-4001 Study In Two Advanced Cancers

  • The FDA has signed off Iovance Biotherapeutics Inc's (NASDAQ:IOVA) Investigational New Drug Application (IND) first genetically modified TIL therapy, IOV-4001, for unresectable or metastatic melanoma and stage III or IV non-small-cell lung cancer (NSCLC).
  • IOV-4001 leverages the gene-editing TALEN technology licensed from Cellectis SA (NASDAQ:CLLS). 
  • A clinical study of IOV-4001 in patients with metastatic melanoma or stage III or IV NSCLC is expected to begin in 2022.
  • Read Next: Iovance's Lifileucel Combo Shows Encouraging Response Rates In Advanced Cancers.
  • A poster highlighting preclinical activity, clinical-scale manufacturing process development, and characterization of IOV-4001 will be presented at American Association for Cancer Research 2022 Annual Meeting. 
  • In the AACR abstract, the anti-tumor activity of IOV-4001 was superior to non-edited TIL and non-edited TIL in combination with anti-PD-1 in a murine model.
  • Price Action: IOVA shares traded 5.92% higher at $13.25 during premarket trading on the last check Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.